Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1991-05-30
1994-10-18
Dentz, Bernard
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548253, 560 51, 560 53, 562459, 562463, A61K 3141, C07D25704
Patent
active
053569199
ABSTRACT:
This invention relates to a compound of the formula: ##STR1## or a pharmaceutically acceptable salt thereof wherein X is oxygen, sulfur, --CH.dbd.CH--, or --CH.dbd.N--; wherein R.sup.1 is --CO.sub.2 R.sup.2 or tetrazole; wherein R.sup.2 is hydrogen, alkyl of 1 to 6 carbons or a pharmaceutically acceptable cation; wherein R is an alkyl of from 1 to 20 carbons, --(CH.sub.2).sub.p CF.sub.3 or --(CH.sub.2).sub.q R.sup.3 wherein R.sup.3 is alkoxy, phenoxy or alkoxy substituted phenoxy wherein the alkoxy group has from 1 to 8 carbons; wherein p and q are integers from 0 to 20; wherein n is 0 or 1; and wherein m is 0, 1, 2, or 3.
REFERENCES:
patent: 3255241 (1966-06-01), Schultz et al.
patent: 3912656 (1975-10-01), Andrews et al.
patent: 3919250 (1975-11-01), Pauling et al.
patent: 4015010 (1977-03-01), Houlihan et al.
patent: 4381360 (1983-04-01), Leistner et al.
patent: 4469885 (1984-09-01), Mueller et al.
Singh et al., Progress in Medicinal Chem., vol. 17, Elsevier, Chapter 4-Medicinal Chem. of Tetrazoles, pp. 151-183 (1980).
Thornber, Chem. Society Reviews, vol. 8, pp. 563-580 (1979).
Fackler, Progress Inorg. Chem., pp. 361-425 (1965).
Djuric Stevan W.
Haack Richard A.
Miyashiro Julie M.
Dentz Bernard
Feder Scott B.
G. D. Searle & Co.
Williams Roger A.
LandOfFree
Leukotriene B.sub.4 synthesis inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Leukotriene B.sub.4 synthesis inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leukotriene B.sub.4 synthesis inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2372809